Percutaneous absorption of betamethasone-17-benzoate, a new topical corticosteroid, was sufficient enough to result in adrenocortical suppression in patients with psoriasis or atopic dermatitis when 0.025% of the steroid cream was applied under occlusion to 30% or more of the body surface, using 9 gm or more of the preparation. The adrenal function returned to normal within a short time after the cream was discontinued.
Mikhail, George R.
"Percutaneous Absorption of Betamethasone-17-Benzoate,"
Henry Ford Hospital Medical Journal
: Vol. 18
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol18/iss3/4